"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Paremyd Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Paremyd (hydroxyamphetamine Hydrobromide 1% and tropicamide 0.25%) is a topical mydriatic used for pupil dilation (mydriasis) in routine diagnostic procedures and in conditions where short-term pupil dilation is desired. Common side effects include increased intraocular pressure, stinging, dryness of the mouth, blurred vision, sensitivity to light, slow heart rate, headache, allergic reactions, nausea, vomiting, pallor, muscle rigidity, central nervous system disturbances, or behavioral disturbances.
The dose of Paremyd is to instill one to two drops in the conjunctival sac. Paremyd may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Paremyd should only be used if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Paremyd (hydroxyamphetamine Hydrobromide 1% and tropicamide 0.25%) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Paremyd FDA Prescribing Information: Side Effects
Increased intraocular pressure has been reported following use of mydriatics. Transient stinging, dryness of the mouth, blurred vision, photophobia with or without corneal staining, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, and muscle rigidity have been reported with the use of tropicamide and/or hydroxyamphetamine hydrobromide, and thus may occur with PAREMYD® (hydroxyamphetamine hydrobromide, tropicamide) Solution. Central nervous system disturbances have also been reported. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse have been reported with the use of anticholinergic drugs. Rare but serious cardiovascular events, including death due to myocardialinfarction, ventricular fibrillation and significant hypotensive episodes have occurred shortly following PAREMYD® (hydroxyamphetamine hydrobromide, tropicamide) instillation.
Read the entire FDA prescribing information for Paremyd (Hydroxyamphetamine Hydrobromide, Tropicamide) »
Additional Paremyd Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.